-
公开(公告)号：EP3141604A1
公开(公告)日：2017-03-15
申请号：EP16183720.8
申请日：2013-12-05
CPC分类号： C12N15/907 , A61K38/00 , C07K7/06 , C07K14/463 , C07K2319/09 , C07K2319/10 , C07K2319/81 , C12N7/00 , C12N9/22 , C12N9/96 , C12N15/102 , C12N15/11 , C12N15/63 , C12N15/67 , C12N15/85 , C12N15/86 , C12N2310/3513 , C12N2750/14143 , C12N2800/22 , C12N2800/80 , C12Y301/00 , C12Y301/21004
摘要： The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
摘要翻译： 本发明提供了RNA引导的内切核酸酶，其被工程化用于在真核细胞或胚胎中表达，以及使用RNA引导的内切核酸酶在真核细胞或胚胎中用于靶向基因组修饰的方法。 还提供了融合蛋白，其中每种融合蛋白包含CRISPR / Cas样蛋白或其片段和效应结构域。 效应结构域可以是切割结构域，表观遗传修饰结构域，转录激活结构域或转录阻遏蛋白结构域。 还提供了使用融合蛋白来修饰染色体序列或调节染色体序列表达的方法。
-
公开(公告)号：EP3138911A1
公开(公告)日：2017-03-08
申请号：EP16183724.0
申请日：2013-12-05
CPC分类号： C12N15/907 , A61K38/00 , C07K7/06 , C07K14/463 , C07K2319/09 , C07K2319/10 , C07K2319/81 , C12N7/00 , C12N9/22 , C12N9/96 , C12N15/102 , C12N15/11 , C12N15/63 , C12N15/67 , C12N15/85 , C12N15/86 , C12N2310/3513 , C12N2750/14143 , C12N2800/22 , C12N2800/80 , C12Y301/00 , C12Y301/21004
摘要： The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
-
公开(公告)号：EP3135765A1
公开(公告)日：2017-03-01
申请号：EP16183719.0
申请日：2013-12-05
CPC分类号： C12N15/907 , A61K38/00 , C07K7/06 , C07K14/463 , C07K2319/09 , C07K2319/10 , C07K2319/81 , C12N7/00 , C12N9/22 , C12N9/96 , C12N15/102 , C12N15/11 , C12N15/63 , C12N15/67 , C12N15/85 , C12N15/86 , C12N2310/3513 , C12N2750/14143 , C12N2800/22 , C12N2800/80 , C12Y301/00 , C12Y301/21004
摘要： The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
-
公开(公告)号：EP3138912A1
公开(公告)日：2017-03-08
申请号：EP16183725.7
申请日：2013-12-05
CPC分类号： C12N15/907 , A61K38/00 , C07K7/06 , C07K14/463 , C07K2319/09 , C07K2319/10 , C07K2319/81 , C12N7/00 , C12N9/22 , C12N9/96 , C12N15/102 , C12N15/11 , C12N15/63 , C12N15/67 , C12N15/85 , C12N15/86 , C12N2310/3513 , C12N2750/14143 , C12N2800/22 , C12N2800/80 , C12Y301/00 , C12Y301/21004
摘要： The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
-
公开(公告)号：EP3138910A1
公开(公告)日：2017-03-08
申请号：EP16183723.2
申请日：2013-12-05
CPC分类号： C12N15/907 , A61K38/00 , C07K7/06 , C07K14/463 , C07K2319/09 , C07K2319/10 , C07K2319/81 , C12N7/00 , C12N9/22 , C12N9/96 , C12N15/102 , C12N15/11 , C12N15/63 , C12N15/67 , C12N15/85 , C12N15/86 , C12N2310/3513 , C12N2750/14143 , C12N2800/22 , C12N2800/80 , C12Y301/00 , C12Y301/21004
摘要： The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
-
6.发明公开CRISPR-BASED GENOME MODIFICATION AND REGULATION 审中-公开CRISPR-BASIERTE GENOMMODIFIZIERUNG UND -REGULIERUNG
公开(公告)号：EP3138909A1
公开(公告)日：2017-03-08
申请号：EP16183717.4
申请日：2013-12-05
CPC分类号： C12N15/907 , A61K38/00 , C07K7/06 , C07K14/463 , C07K2319/09 , C07K2319/10 , C07K2319/81 , C12N7/00 , C12N9/22 , C12N9/96 , C12N15/102 , C12N15/11 , C12N15/63 , C12N15/67 , C12N15/85 , C12N15/86 , C12N2310/3513 , C12N2750/14143 , C12N2800/22 , C12N2800/80 , C12Y301/00 , C12Y301/21004
摘要： The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
摘要翻译： 本发明提供了用于在真核细胞或胚胎中表达的RNA引导的内切核酸酶，以及使用RNA引导的内切核酸酶在真核细胞或胚胎中靶向基因组修饰的方法。 还提供了融合蛋白，其中每个融合蛋白包含CRISPR / Cas样蛋白或其片段和效应结构域。 效应结构域可以是切割结构域，表观遗传修饰结构域，转录激活结构域或转录阻遏物结构域。 还提供了使用融合蛋白修饰染色体序列或调节染色体序列表达的方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.011 秒)
